Wells Fargo analyst Mike Mayo maintains Goldman Sachs Group (NYSE:GS) with a Overweight and lowers the price target from $420 to $380.
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris reiterates business plans for ongoing programs.
